Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University)(Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University)) - 药物靶点：CD19_在研适应症：B细胞淋巴瘤，B细胞恶性肿瘤_专利_临床

概要

基本信息

药物类型

自体CAR-T

别名-

靶点

CD19

作用方式

抑制剂

作用机制

CD19抑制剂(B淋巴细胞抗原CD19抑制剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病

在研适应症

B细胞淋巴瘤B细胞恶性肿瘤

非在研适应症-

原研机构

徐州医科大学附属医院

在研机构

徐州医科大学附属医院

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)临床2期

特殊审评-

登录后查看时间轴

关联

8

项与 Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University) 相关的临床试验

NCT05755828

/ Recruiting临床2期IIT

Prospective, Multicenter, Open, One-arm Clinical Study of Safety and Efficacy of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma

To evaluate the CR rate of B-NHL subjects who achieved PR at intermediate assessment after first-line chemotherapy treated with autologous stem cell transplantation + Anti-CD19 CAR T cells.

开始日期2022-12-01

申办/合作机构

徐州医科大学附属医院

ChiCTR1900027239

/ Recruiting早期临床1期IIT

Combination of humanized anti-CD19 CAR-T and anti-BCMA CAR-T versus autogolous hematopoietic stem cell transplantation for non-complete remission multiple myeloma: a single center, open-label, randomized controlled trial

开始日期2019-11-01

申办/合作机构-

ChiCTR1900026219

/ Recruiting早期临床1期IIT

Combination of humanized anti-CD19 CAR-T and anti-BCMA CAR-T versus anti-BCMA CAR-T alone for relapsed or refractory multiple myeloma:a multicenter, open-label, randomized controlled trial

开始日期2019-10-01

申办/合作机构

徐州医科大学附属医院

100 项与 Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University) 相关的临床结果

登录后查看更多信息

100 项与 Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University) 相关的转化医学

登录后查看更多信息

100 项与 Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University) 相关的专利（医药）

登录后查看更多信息

100 项与 Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University) 相关的药物交易

登录后查看更多信息